TNFSF13B and autoimmune disease: The aberrant activation of APRIL and BAFF leads to dysregulated B cell growth; therefore, they are attractive therapeutic targets for B cell malignancies and autoimmune diseases (Bolkun et al., 2014; Briones et al., 2002; Carpenter et al., 2013; Chiu et al., 2007).